Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2003; 90(02): 165-166DOI: 10.1055/s-0037-1613488 Editorial Focus Schattauer GmbH Optimizing initial therapy of acute venous thromboembolism Authors Author Affiliations Andrew I. Schafer 1 Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA Recommend Article Abstract Buy Article(opens in new window) Full Text References References 1 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1: 1309-12. 2 Hirsh J, Warkentin TE, Shaughnessy SG. et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: S64-S94. 3 Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. for the CORTES Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-31. 4 Kakkar VV, Hoppenstead DA, Fareed J. et al. Randomized trial of different regiments of heparin and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99: 1965-70. 5 Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Semin Thromb Hemost 2001; 27: 513-8. 6 Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989; 8: 65-8. 7 Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 1988; 2: 239-56. 8 Riess H, Koppenhager K, Tolle A. et al. for the TH-4 Study Group. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep vein thrombosis. Thromb Haemost 2003; 90: 252-9. 9 Anand SS, Bates S, Ginsberg JS. et al. Recurrent venous thrombosis and heparin therapy. An evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 159: 2029-32. 10 The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102: 2726-31.
